Premium
Effects of single nucleotide polymorphisms in human N‐acetyltransferase 2 on metabolic activation (O‐acetylation) of heterocyclic amine carcinogens
Author(s) -
Hein David W.,
Fretland Adrian J.,
Doll Mark A.
Publication year - 2006
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.21957
Subject(s) - heterocyclic amine , acetylation , acetyltransferase , n acetyltransferase , carcinogen , single nucleotide polymorphism , chemistry , mutagen , biochemistry , genotype , microbiology and biotechnology , biology , gene
N‐Acetyltransferase 2 (NAT2) catalyzes the O‐acetylation of N‐hydroxy heterocyclic amines such as N‐hydroxy‐2‐amino‐3,8‐dimethylimidazo[4,5‐f]quinoxaline (NOHMeIQx) and N‐hydroxy‐2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐b] pyridine (NOH PhIP) to DNA binding metabolites that initiate mutagenesis and carcinogenesis. NAT2 acetylator phenotype is associated with increased cancer risk. Single nucleotide polymorphisms (SNPs) have been identified in the NAT2 coding region. Although the effects of these SNPs on N‐acetyltransferase activity have been reported, very little is known regarding their effects on O‐acetylation activity. To investigate the functional consequences of SNPs in the NAT2 coding region on the O‐acetylation of N‐hydroxy heterocyclic amines, reference NAT2*4 and NAT2 variant alleles possessing one were cloned and expressed in yeast ( Schizosaccaromyces pombe ). T111C, C282T, C481T, C759T, and A803G (K268R) SNPs did not significantly ( p > 0.05) modify O‐acetylation catalysis with NOHPhIP or NOHMeIQx. C190T (R64W), G191A (R64Q), T341C (I114T), A434C (E145P), G590A (R197Q) and A845C (K282T) significantly ( p < 0.01) reduced the O‐acetylation of both NOHPhIP and NOHMeIQx, whereas G857A (G286E) significantly ( p < 0.05) decreased catalytic activity towards the O‐acetylation of NOHMeIQx but not NOHPhIP. These results have important implications towards the interpretation of molecular epidemiological studies of NAT2 genotype and cancer risk. © 2006 Wiley‐Liss, Inc.